Literature DB >> 16596771

Cannabinoid receptor signaling.

A C Howlett1.   

Abstract

The cannabinoid receptor family currently includes two types: CB1, characterized in neuronal cells and brain, and CB2, characterized in immune cells and tissues. CB1 and CB2 receptors are members of the superfamily of seven-transmembrane-spanning (7-TM) receptors, having a protein structure defined by an array of seven membrane-spanning helices with intervening intracellular loops and a C-terminal domain that can associate with G proteins. Cannabinoid receptors are associated with G proteins of the Gi/o family (Gi1, 2 and 3, and Go1 and 2). Signal transduction via Gi inhibits adenylyl cyclase in most tissues and cells, although signaling via Gs stimulates adenylyl cyclase in some experimental models. Evidence exists for cannabinoid receptor-mediated Ca2+ fluxes and stimulation of phospholipases A and C. Stimulation of CB1 and CB2 cannabinoid receptors leads to phosphorylation and activation of p42/p44 mitogen-activated protein kinase (MAPK), p38 MAPK and Jun N-terminal kinase (JNK) as signaling pathways to regulate nuclear transcription factors. The CB1 receptor regulates K+ and Ca2+ ion channels, probably via Go. Ion channel regulation serves as an important component of neurotransmission modulation by endogenous cannabinoid compounds released in response to neuronal depolarization. Cannabinoid receptor signaling via G proteins results from interactions with the second, third and fourth intracellular loops of the receptor. Desensitization of signal transduction pathways that couple through the G proteins probably entails phosphorylation of critical amino acid residues on these intracellular surfaces.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16596771     DOI: 10.1007/3-540-26573-2_2

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN: 0171-2004


  151 in total

1.  Regulation of hippocampal cannabinoid CB1 receptor actions by adenosine A1 receptors and chronic caffeine administration: implications for the effects of Δ9-tetrahydrocannabinol on spatial memory.

Authors:  Vasco C Sousa; Natália Assaife-Lopes; Joaquim A Ribeiro; Judith A Pratt; Ros R Brett; Ana M Sebastião
Journal:  Neuropsychopharmacology       Date:  2010-10-06       Impact factor: 7.853

2.  Cannabinoid CB1 receptors transactivate multiple receptor tyrosine kinases and regulate serine/threonine kinases to activate ERK in neuronal cells.

Authors:  George D Dalton; Allyn C Howlett
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

3.  The Central Role of Glia in Pathological Pain and the Potential of Targeting the Cannabinoid 2 Receptor for Pain Relief.

Authors:  Jenny L Wilkerson; Erin D Milligan
Journal:  ISRN Anesthesiol       Date:  2011

4.  Epidermal growth factor receptor transactivation by the cannabinoid receptor (CB1) and transient receptor potential vanilloid 1 (TRPV1) induces differential responses in corneal epithelial cells.

Authors:  H Yang; Z Wang; J E Capó-Aponte; F Zhang; Z Pan; P S Reinach
Journal:  Exp Eye Res       Date:  2010-07-07       Impact factor: 3.467

Review 5.  International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB₁ and CB₂.

Authors:  R G Pertwee; A C Howlett; M E Abood; S P H Alexander; V Di Marzo; M R Elphick; P J Greasley; H S Hansen; G Kunos; K Mackie; R Mechoulam; R A Ross
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

6.  Cannabinoid CB(2) receptors modulate ERK-1/2 kinase signalling and NO release in microglial cells stimulated with bacterial lipopolysaccharide.

Authors:  Stefania Merighi; Stefania Gessi; Katia Varani; Carolina Simioni; Debora Fazzi; Prisco Mirandola; Pier Andrea Borea
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

7.  Unique effects of compounds active at both cannabinoid and serotonin receptors during stroke.

Authors:  Ming Zhang; Anu Mahadevan; Mukkanti Amere; Hongbo Li; Doina Ganea; Ronald F Tuma
Journal:  Transl Stroke Res       Date:  2012-07-26       Impact factor: 6.829

8.  A cytochrome P450-derived epoxygenated metabolite of anandamide is a potent cannabinoid receptor 2-selective agonist.

Authors:  Natasha T Snider; James A Nast; Laura A Tesmer; Paul F Hollenberg
Journal:  Mol Pharmacol       Date:  2009-01-26       Impact factor: 4.436

Review 9.  Cannabinoids and GI Disorders: Endogenous and Exogenous.

Authors:  Zachary Wilmer Reichenbach; Ron Schey
Journal:  Curr Treat Options Gastroenterol       Date:  2016-12

Review 10.  Medical Cannabis for Older Patients.

Authors:  Amir Minerbi; Winfried Häuser; Mary-Ann Fitzcharles
Journal:  Drugs Aging       Date:  2019-01       Impact factor: 3.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.